

B 21852 E

HEALTH SCIENCES LIBRARY
University of Wisconsin
1305 Linden Dr., Madison, Wis. 53706

AUG 21 1980

Volume 14
No. 1 - 1980
July

clinical *nephrology*

An International Journal



Dustri-Verlag
Dr. Karl Feistle
München-
Deisenhofen

clinical nephrology

Volume 14



Duster-Verlag
Dr. Karl Feistle
München-
Deisenhofen

EDITOR-IN-CHIEF:

R. Kluthe, Freiburg

EDITORS:

J. Bergström, Stockholm
J. S. Cameron, London
K. Lange, New York
M. Legrain, Paris
P. Michielsen, Leuven
W. Siegenthaler, Zürich

ASSISTANT EDITORS:

S. R. Batsford, Freiburg
M. Michelis, New York
C. S. Ogg, London

EDITORIAL BOARD:

H. Abe, Osaka
A. Aperia, Stockholm
M. Arakawa, Niigata
A. W. Asscher, Cardiff
A. Astrug, Sofia
E. L. Becker, Chicago
A. F. Bergstrand, Stockholm
M. Bewick, London
A. Blumberg, Aarau
A. Bohle, Tübingen
J. Brod, Hannover
J. Brodehl, Hannover
E. Buchborn, Munich
H. Bucht, Göteborg
B. T. Burton, Bethesda
A. R. Clarkson, Adelaide
J. W. Coburn, Los Angeles
R. Cotran, Boston
P. Deetjen, Innsbruck
P. v. Dittrich, Innsbruck
R. Donckerwolcke, Utrecht
P. D. Doolan, Waterbury
J. Dormont, Paris
H. Dutz, Berlin
R. Dzurik, Bratislava
Th. Ehrenreich, Brooklyn
J. P. H. J. Fillastre, Rouen
R. B. Freemann, Rochester
E. A. Friedman, New York
D. Fries, Paris
L. E. Gelin, Göteborg
U. Gessler, Nürnberg
C. Giordano, Naples
D. Goldsmith, New York
I. Greifer, New York
R. Habib, Paris
J. Hardwicke, Birmingham

M. Hatano, Tokyo
O. Heidenreich, Aachen
D. Höffler, Darmstadt
I. B. Houston, Manchester
J. C. Hunt, Memphis
C. Jacobs, Paris
N. F. Jones, London
M. Kaye, Montreal
E. Kemp, Odense
A. C. Kennedy, Glasgow
D. N. S. Kerr, Newcastle upon Tyne
C. M. F. T. Kjellstrand, Minneapolis
H. Klinkmann, Rostock
J. Kopple, Los Angeles
J. G. G. Ledingham, Oxford
H. Losse, Münster
J. F. Maher, Farmington
J. F. Mahony, Sydney
S. G. Massry, Los Angeles
D. Maude, New York
L. Migone, Parma
J. F. Moorhead, London
J. D. K. North, Auckland
J. Ofstad, Bergen
S. Olsen, Aarhus
T. Orłowski, Warsaw
S. Papper, Oklahoma City
V. Parsons, London
M. M. Reidenberg, New York
E. Renner, Cologne
F. Rényi-Vámos, Budapest
F. Reubi, Bern
B. H. B. Robinson, Birmingham
B. Rodriguez-Iturbe, Maracaibo
P. Royer, Paris
H. Sarre, Freiburg
H. G. Sieberth, Cologne
E. A. H. Sims, Burlington
J. F. Soothill, London
B. Spargo, Chicago
J. M. Suc, Toulouse
K. Schärer, Heidelberg
W. Schoeppe, Frankfurt
O. Schück, Prague
S. Shibata, Tokyo
G. S. Spear, Orange (California)
E. M. Tareev, Moscow
W. Thoenes, Mainz
J. Traeger, Lyon
G. Treser, New York
A. Valek, Prague
R. K. A. Verberckmoes, Leuven
A. Vogt, Freiburg
C. B. Wilson, La Jolla
H. P. Wolff, Mainz
S. Zaltzman, Mexico City
H. U. Zollinger, Basel

PUBLISHER:

DUSTRI-VERLAG Dr. Karl Feistle,
Bahnhofstraße 5, Postfach 49,
D-8024 München-Deisenhofen,
Telephon München (089) 6132352,
Germany.

EDITOR-IN-CHIEF:

Prof. Dr. med. R. Kluthe,
P. O. Box 5269
D-7800 Freiburg (Germany).

MANUSCRIPTS:

Should be submitted to
Reinhold Kluthe, M. D.,
or: Kurt Lange, M. D., American Editor
Clinical Nephrology
Lenox Hill Hospital
100 East 77th Street
New York, N. Y. 10021, U.S.A.

ADVERTISING:

Representatives in USA:
Charles C. Cunningham, Inc.,
P. O. Box 308, Park Ridge, N.J., 07656,
telephone, (201) 391-3210
and Charles B. Healy,
P. O. Box 1295, Pacific Palisades,
California 90272.

Germany:

H. P. Eckardt,
DUSTRI-VERLAG Dr. Karl Feistle

Volumes 13 and 14 (6 issues per volume)
will be published in 1980.
Published monthly.
Subscription price for 1980: DM 224,-
US \$ 98,50 plus postage. Single copies:
DM 21,- US \$ 11,- plus postage

Parallel editions in microfiche can be
purchased. Prices on order.

Application to mail at Second Class
postage rate paid at Jamaica, N. Y. 11431
Air freight and mailing in the U.S. by
Publications Expediting, Inc. 200 Meacham
Ave., Elmont, L. I., N. Y. 11003.

Available from all booksellers or direct
from the publisher.

All orders must be accompanied by
payment. The subscription will be renewed
automatically each year unless cancelled
prior to the fourth week before the end of
the year.

This journal is regularly listed in Current
Contents.

© 1980 DUSTRI-VERLAG Dr. Karl Feistle,
München-Deisenhofen (Germany)
All rights reserved (including those of
translation into foreign languages). No part
of this journal may be reproduced in any
form - by photoprint, microfilm, or any
other means - nor transmitted or
translated into a machine language
without the permission in writing of the
publisher. Registered names, trademarks,
etc. used in this journal, even without
specific indication thereof, are not to be
considered unprotected by law.
Printed in West Germany
by Mayr Miesbach GmbH,
Am Windfeld 15,
D-8160 Miesbach, Germany.
Telex 0526115
ISSN 0301-0430

The effects of azathioprine and prednisolone on T- and B-lymphocytes in patients with lupus nephritis and chronic glomerulonephritis

I. E. TAREYEVA, E. M. SHILOV and N. B. GORDOVSKAYA

Laboratory of Nephrology and Clinic of Internal Medicine, 1st Moscow Medical Setchenov's Institute, 11 a Rossolimo str., 119021 Moscow, USSR

Abstract. The effects of long-term treatment with azathioprine and prednisolone on T- and B-lymphocytes were studied in 52 patients with lupus nephritis (LN) and chronic glomerulonephritis (GN). The effect of azathioprine on lymphocyte populations was dose dependent; high doses decreased the number of T- and particularly, B-cells, while smaller doses produced a selective depletion of B-cells. The changes in T- and B-cells during prednisolone treatment were variable with alternating increases and decreases in their numbers. The patients with increased B-lymphocyte levels showed the best response to immunosuppressive therapy.

The effects produced by immunodepressants upon the T- and B-lymphocyte systems are important because of the different effector mechanisms of humoral and cellular immunity in the pathogenesis of certain autoimmune diseases. The anti-proliferative effect of cyclophosphamide is known to be more pronounced on B-lymphocytes. With azathioprine the findings appear to be conflicting.

The therapeutic efficacy of corticosteroids and cytostatics is generally associated with inhibition of immunological reactions (in addition to nonspecific anti-inflammatory action), thus leading to their use in patients with high immunological activity. The correlation between the level of T-lymphocytes and disease activity in systemic lupus erythematosus (SLE) is well documented [Schelnberg and Cathcart 1974, Hamilton and Winfield 1979], while the data concerning B-lymphocytes is conflicting [Messner et al. 1973, Arimori et al. 1975, Sandhofer et al. 1975]. The same applies to T- and B-cell numbers in patients with glomerulonephritis [Tishkov et al. 1976, Zucchelli et al. 1976]. Thus further studies of the T- and B-cell levels in SLE and GN patients are warranted.

The present study was designed to: 1) reveal correlations between numbers of T- and B-cells and disease activity in lupus nephritis (LN) and chronic GN; 2) study the effect of long-term therapy with azathioprine and prednisolone on T- and B-cells in LN and GN patients; 3) evaluate the dependence of

the efficacy of treatment on the initial T- and B-cell levels.

Materials and methods

Patients: The levels of T- and B-lymphocytes were studied in 110 patients (70 with GN and 40 with LN) aged 15 to 57 years and in 33 age- and sex-matched normal subjects. The effect of azathioprine and prednisolone on T- and B-lymphocytes was studied in 52 LN and GN patients.

Fifty-eight patients had chronic GN and 12 patients had acute poststreptococcal GN. Renal biopsy specimens were obtained in 37 patients with chronic GN: 11 had mesangio-proliferative GN, 5-mesangio-membranous, 6-membranous GN, 2-mesangio-capillary GN, 2-lobular GN and 11-fibroplastic GN. Immunofluorescence was studied in 28 cases: IgG was demonstrated in glomeruli in 18 cases, IgM - in 6, IgA - in 3 and fibrin - in 4 cases.

At the time of study, 15 of the 40 LN patients had active SLE with nephritis and multiple systemic signs, 13 had active LN without extrarenal manifestations and 12 had inactive disease. Renal biopsy (21 patients) revealed diffuse proliferative LN in 6 patients, focal proliferative - in 8, membranous - in 2 and fibroplastic - in 5. IgG was found in glomeruli in 12 out of 16 cases studied by immunofluorescent methods.

At the start of the study 103 out of 110 patients were receiving no immunodepressive drugs; 7 patients with active SLE were receiving low doses of prednisolone (5-15 mg/day).

Received January 31, 1980, in revised form April 24, 1980.

Reprint requests to Dr. I. E. Tareyeva.

This material may be protected by Copyright law (Title 17 U.S. Code)

The effect of azathioprine was studied in 12 patients (2 with LN and 10 with GN), whereas that of prednisolone was studied in 28 patients (18 with LN and 10 with GN); a combination of azathioprine and prednisolone was studied in 12 patients (2 with LN and 10 with GN). During the first month of treatment investigations were carried out every 7 days and from the second month of treatment every 3-4 weeks.

In order to exclude the possibility of spontaneous variations in T- and B-cell level, studies were repeated (2 to 6 times) for 2 to 64 weeks in 6 healthy donors and in 15 LN and GN patients who were not given any immunosuppressive agents.

Lymphocytes were isolated from heparinized venous blood using a Ficoll-Hypaque gradient. The resulting suspension contained 85-90% lymphocytes with viability greater than 95% as assessed by trypan blue exclusion. Monocytes were detected by incubating mononuclear cells with latex particles.

B-lymphocytes were counted after immunofluorescent labelling of membrane-bound immunoglobulin. The cells were incubated at 37° for 30 minutes before the addition of fluorescent antiserum to eliminate serum IgG fixed to Fc receptors and antilymphocyte antibodies. This allowed the exclusion of cells having receptors for Fc fragments of IgG [Lobo et al. 1975] so that only B-lymphocytes were counted. Under these conditions the mean percentage of Ig-bearing B-lymphocytes in normal subjects was $9.7 \pm 0.4\%$.

T-lymphocytes were studied by the E-rosette formation technique using sheep erythrocytes (SRBC) [Jondal et al. 1972], without pretreatment of SRBC with neuraminidase and without the addition of serum to lymphocyte and erythrocyte suspensions. Lymphocytes which did not carry membrane-bound immunoglobulins and which did not form E-rosettes were designated as null cells [Froland et al. 1974]. The percentage of E-rosette forming cells ($51.4 \pm 2.3\%$) was lower than that usually described, and the percentage of O-cells was higher and included a small number of T-cells.

Results

The numbers of T- and B-lymphocytes in LN and GN patients are presented in Table 1. During exacerbation of disease the proportion of B-lymphocytes in all groups of patients increased with simultaneous reduction of the proportion of T-cells. These changes were most marked in patients with active SLE (B- $19.7 \pm 2.0\%$; T- $29.3 \pm 3.1\%$) who also had an increased percentage of null lymphocytes ($51.0 \pm 3.4\%$).

Absolute numbers of T- and B-lymphocytes also reflected the activity of disease, but contrary to the percentage counts, differed in GN and LN. Most GN patients had a lymphocytosis with an increased absolute number of B- and null lymphocytes, and a normal T-cell count. On the contrary, in patients with active

Table 1 Levels of B-, T-, O-cells and total lymphocyte count in GN and LN patients before treatment (mean \pm SD).

| Patients | Lymphocytes | Total | | | T | | | O | |
|-----------------------|-------------|----------------|----------------|-----------------|----------------|-----------------|----------------|-----------------|--|
| | | number | % | mm ³ | % | mm ³ | % | mm ³ | |
| Acute GN | (n=12) | 2343 \pm 352 | 12.9 \pm 1.8 | 256 \pm 28 | 39.8 \pm 4.5 | 840 \pm 102 | 47.3 \pm 5.4 | 1284 \pm 218 | |
| | | P<0.02* | <0.02 | <0.01 | <0.05 | | >0.05 | <0.01 | |
| Chronic GN: | | | | | | | | | |
| active | (n = 39) | 2144 \pm 154 | 16.5 \pm 1.1 | 356 \pm 32 | 42.8 \pm 2.8 | 865 \pm 108 | 41.6 \pm 2.6 | 984 \pm 82 | |
| | | P<0.05 | <0.01 | <0.01 | <0.05 | | | <0.01 | |
| inactive | (n=19) | 1704 \pm 154 | 9.2 \pm 0.9 | 153 \pm 17 | 48.0 \pm 3.1 | 824 \pm 96 | 44.0 \pm 3.2 | 779 \pm 97 | |
| | | | | >0.1 | | | | >0.1 | |
| LN: | | | | | | | | | |
| with systemic lesions | (n = 15) | 505 \pm 44 | 19.7 \pm 2.0 | 93 \pm 10 | 29.3 \pm 3.1 | 156 \pm 26 | 51.0 \pm 3.4 | 263 \pm 35 | |
| | | P<0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.05 | <0.01 | |
| isolated | (n=13) | 1569 \pm 177 | 17.1 \pm 2.4 | 250 \pm 30 | 35.3 \pm 3.2 | 582 \pm 77 | 48.8 \pm 3.9 | 782 \pm 83 | |
| | | P>0.1 | <0.01 | <0.01 | <0.01 | <0.02 | >0.05 | >0.1 | |
| in remission | (n=12) | 1430 \pm 90 | 9.6 \pm 2.9 | 140 \pm 17 | 44.3 \pm 4.0 | 621 \pm 78 | 46.1 \pm 4.1 | 672 \pm 76 | |
| | | P<0.01 | >0.1 | <0.1 | >0.1 | <0.05 | >0.1 | | |
| Normals | (n=33) | 1764 \pm 70 | 9.7 \pm 0.4 | 173 \pm 11 | 51.4 \pm 2.3 | 844 \pm 60 | 41.6 \pm 2.4 | 682 \pm 17 | |

* P values are for comparison with normals.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.